International Journal of Ayurveda Research International Journal of Ayurveda Research
  About IJAR | Editors | Search | Current Issue | Archives | Ahead Of Print | Instructions | Online submission | Advertise | Contact Us | Login 
Users Online: 32   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
ORIGINAL ARTICLE
Year : 2010  |  Volume : 1  |  Issue : 4  |  Page : 216-219

Efficacy and safety of livwin (polyherbal formulation) in patients with acute viral hepatitis: A randomized double-blind placebo-controlled clinical trial


1 Department of Pharmacology, Indira Gandhi Government Medical College, Nagpur - 440 018, India
2 Department of Medicine, Indira Gandhi Government Medical College, Nagpur - 440 018, India

Correspondence Address:
Yogendra Keche
Department of Pharmacology, Smt. Kashibai Navale Medical College and Hospital, Narhe, off Pune - Bangalore Westerly Bypass Highway, Near Dhayari Phata, Pune
India
Login to access the Email id


DOI: 10.4103/0974-7788.76784

PMID: 21455448

Get Permissions

Objectives: The study was planned to evaluate the efficacy and safety of Livwin (polyherbal formulation) in acute viral hepatitis. Materials and Methods: In this study, there were 29 patients in each group, receiving either Livwin (containing Ashwagandha, Arjuna, Bhumyamalaki, Daruharidra, Guduchi, Kutki and Punarnava) or placebo capsules containing lactose powder (500 mg). Both drugs were given orally two capsules two times a day for eight weeks followed by treatment free period of four weeks. Recovery of patients was assessed by noting symptomatic recovery and by measuring levels of serum bilirubin, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), alkaline phosphatase at baseline, 2, 4, 8 and 12 weeks. Results: Significant earlier recovery of weakness was observed with Livwin as compared to placebo at 2, 4 and 8 weeks. Serum bilirubin and ALT was observed in normal range in significantly more number of patients with Livwin treatment as compared to placebo at 2, 4 and 8 weeks. AST was observed in normal range in significantly more number of patients with Livwin treatment as compared to placebo at 2 and 4 weeks. Conclusions: Livwin is found effective in uncomplicated patients of acute viral hepatitis. Epigastric pain and diarrhea were reported with Livwin treatment.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1898    
    Printed234    
    Emailed0    
    PDF Downloaded378    
    Comments [Add]    
    Cited by others 1    

Recommend this journal